Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
NCT05949281Phase 2Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Jan 2031
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of colchicine in type 1 diabetes mellitus (T1D), cardiovascular disease (CVD), chronic inflammation. Started Aug 2023; status: active, not recruiting.
02
Drugs
colchicine
03
Conditions
type 1 diabetes mellitus (T1D)cardiovascular disease (CVD)chronic inflammation
Beyond the preview
Go deeper on NCT05949281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949281.